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Objective: Neurocognitive impairment is commonly reported at onset of psychotic
disorders. However, the long-term neurocognitive course remains largely uninvestigated
in first episode psychosis (FEP) and the relationship to clinically significant subgroups even
more so. We report 10 year longitudinal neurocognitive development in a sample of FEP
patients, and explore whether the trajectories of cognitive course are related to presence
of relapse to psychosis, especially within the first year, with a focus on the course of verbal
memory.
Method: Forty-three FEP subjects (51% male, 28 ± 9 years) were followed-up
neurocognitively over five assessments spanning 10 years. The test battery was divided
into four neurocognitive indices; Executive Function, Verbal Learning, Motor Speed, and
Verbal Fluency. The sample was grouped into those relapsing or not within the first,
second and fifth year.
Results: The four neurocognitive indices showed overall stability over the 10 year period.
Significant relapse by index interactions were found for all indices except Executive
Function. Follow-up analyses identified a larger significant decrease over time for the
encoding measure within Verbal Memory for patients with psychotic relapse in the first
year [F 2(4, 38) = 5.8, p = 0.001, η = 0.40].
Conclusions: Main findings are long-term stability in neurocognitive functioning in FEP
patients, with the exception of verbal memory in patients with psychotic relapse or
non-remission early in the course of illness. We conclude that worsening of specific parts
of cognitive function may be expected for patients with on-going psychosis, but that the
majority of patients do not show significant change in cognitive performance during the
first 10 years after being diagnosed.
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INTRODUCTION
While cognitive deficits are frequently reported in first-episode
psychosis (FEP) (Bilder et al., 2000; Addington et al., 2003; Kurtz,
2005), the longitudinal course remains an area of debate (Rund,
1998; Townsend and Norman, 2004). Most longitudinal studies
of neurocognition in FEP refer to follow-up intervals of 2–5 years,
describing stability or small improvements over time (Gold et al.,
1999; Hoff et al., 1999; Hill et al., 2004; Rund et al., 2007). A few
studies covering 10 or more years after first episode (Stirling et al.,
2003; Hoff et al., 2005) or early onset schizophrenia (Oie et al.,
2010) provide contrasting results ranging from overall stability to
selective deterioration or developmental arrest.
Inconsistent findings are generally explained by methodolog-
ical challenges, such as use of multiple test batteries assess-
ing a variety of domains over different lengths of follow-up
periods (Bozikas and Andreou, 2011). Further, treatment with
antipsychotic medication may improve neurocognitive perfor-
mance (Bilder et al., 2002) although the decrement from normal
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performance remains (Keefe et al., 2006). Thus, different types
and effects of medication may confound interpretations of neu-
rocognitive change.
Clinical subgroups with FEP most likely experience different
neurocognitive trajectories that are concealed when the groups
are merged and averaged over time. In an attempt to iden-
tify longitudinally emerging subgroups, cross-sectional studies
have compared FEP- and multi-epsiode patients. Such stud-
ies tend to report lower performances in multi-episode sam-
ples (Pukrop et al., 2006; Braw et al., 2008; Sponheim et al.,
2010).The cross-sectional method leaves open the possibility
that group differences stem from incomplete sample matching
(Rund, 1998; Moritz et al., 2002), in that well-functioning FEP
patients drop out from mental health care follow-ups (Braw
et al., 2008). Also, there is a risk of biased sample selection
(Braw et al., 2008) in which poor outcome patients are selected
to the multi-episode samples. To date, investigations of a rela-
tionship between neurocognitive course and recurrent psychotic
episodes are not reported in studies of FEP patients with a longi-
tudinal multi-assessment design. Consequently, it is still unclear
whether cognitive dysfunctions remain stable, decrease, or fluc-
tuate (Rodriguez-Sanchez et al., 2008), and if there are systematic
differences between clinically defined subgroups (Knoll et al.,
1998).
The early phase of psychosis has been referred to as a
“critical period” in the course of illness, suggesting that when
deterioration occurs, it proceeds aggressively in the first 2–3
years, with subsequent relative stability (Birchwood et al., 1998;
Crumlish et al., 2009). Whether the hypothesis of a critical period
also applies to the course of neurocognitive functions remains
unknown.
Identifying and describing subgroups is a commonly used
method in the effort to reduce heterogeneity and increase under-
standing of psychotic disorders and their progression. In terms
of neurocognitive heterogeneity, there is an on-going debate on
specific vs. more generalized cognitive impairments, especially
surrounding illness onset (Lencz et al., 2006).
Verbal memory dysfunction is one of the most consistently
reported cognitive deficits and among the best predictors of func-
tional outcome in schizophrenia (Toulopoulou andMurray, 2004;
Koutsouleris et al., 2012). Also executive function is reported to
contribute in predicting transition to psychosis in at-risk patients
(Chan et al., 2006).
However, it has been argued that specific effects are small com-
pared to a generalized effect in schizophrenia (Dickinson et al.,
2008).
Controversies on patterns and size of deficits may be inter-
preted in light of the aforementioned potential critical period; in
which certain domains may develop into relatively more distinct
deficit profiles, causing the degree of impairment to be highly
influenced by the timing of assessment (Gonzalez-Blanch et al.,
2006).
A recent meta-analytic review found that cognitive impair-
ments for verbal learning and memory or encoding were greatest
in the early phase of the illness (Mesholam-Gately et al., 2009).
This is consistent with the reports by Heinrichs and Zakzanis
(1998) and others (Cirillo and Seidman, 2003) who argue that
if a selective or disproportionate cognitive deficit does exist at
the “domain level” in schizophrenia, it would be in the domain
of verbal declarative memory (Saykin et al., 1991; Mesholam-
Gately et al., 2009; Kern et al., 2010; Bozikas and Andreou, 2011).
Therefore, narrowing focus from global to more specific areas of
neurocognition seems justified, and is of particular importance to
this patient group.
Verbal memory impairment is reported to be a potential
genetic marker of vulnerability in non-affected relatives (Skelley
et al., 2008), and in high-risk individuals that subsequently tran-
sit to psychosis (Fusar-Poli et al., 2012; Giuliano et al., 2012).
Further, verbal memory deficits indicate a more rapid conver-
sion to psychosis (Seidman et al., 2010; Koutsouleris et al., 2012)
through the prodromal period and the onset of a first-episode
(Pukrop et al., 2007; Valli et al., 2012). Additionally, over the long-
term, there appears to be some evidence of a further deterioration
in verbal memory, contrasting a pattern of general neurocog-
nitive stability over time (Bozikas and Andreou, 2011). Verbal
learning is also related to insight (Buchy et al., 2010; Engh et al.,
2011; Wiffen et al., 2012), and social functioning in psychotic ill-
nesses (Stain et al., 2012), making it an area of high importance
to clinical therapy and rehabilitation.
Thus, verbal memory and disease progression appear to be
closely associated through the early phases of illness. This rela-
tionship may also be evident in a long-term perspective, possibly
mediated through an early critical period.
To explore this hypothesis requires longitudinal studies of FEP
patients, applying multiple assessments and detailed clinical and
neurocognitive data.
In previous reports from the TIPS study (Rund et al., 2007;
Barder et al., 2013) we concluded that the overall neurocogni-
tive course remained stable during the first 2–5 years after illness
onset. However, mild cognitive deterioration was observed in ver-
bal learning and motor speed, and applied to patients having
experienced more than one psychotic episode during the 5 year
span compared to those with a stable remission of their index psy-
chosis, i.e., a single episode and no re-occurring episodes Barder
et al. (2013). In this study we ask if the same holds true over a 10
year period, based on recurrent episodes (relapses) of psychosis
within the first year after treatment.
RESEARCH QUESTIONS
(1) Does neurocognitive functioning change over the 10 year
period from start of treatment in FEP patients?
(2) Does illness severity (“Early relapse or no early relapse”) dif-
ferentiate the longitudinal neurocognitive trajectory in FEP
patients?
(3) Does evidence support global or specific neurocognitive
change related to illness severity over a 10 year follow-up
period, and is verbal memory especially sensitive?
MATERIALS AND METHODS
THE TIPS PROJECT
The present report originates from the Early Treatment and
Intervention in Psychosis Study (TIPS), a prospective longitu-
dinal study of the relationship between duration of untreated
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psychosis (DUP) and outcome in FEP. The study was carried out
in four Scandinavian health care sectors; three in Norway (Oslo,
Stavanger and Haugesund) and one in Denmark (Roskilde). The
project has been approved by the Regional Committee forMedical
Research Ethics Health Region II and Health Region East in
Norway, and The regional committee for science ethics region
Sjælland, Denmark. Informed consent was obtained from all
participants.
A total of 301 patients between 15–65 years of age were
included in the TIPS study. All patients met the DSM-IV cri-
teria for non-organic psychosis, were actively psychotic without
previously receiving adequate antipsychotic treatment at time of
inclusion, and were included in a defined treatment program
(Melle et al., 2004). Of the total group, 213 patients were older
than17 years and available for neuropsychological testing after
remission of the psychotic symptoms within the first 3 months
(defined as a score lower than 4 on the relevant PANSS posi-
tive symptoms (Kay et al., 1987), or after 3 months when the
patient gave consent and could cooperate, irrespective of remis-
sion. All patients were invited for reassessment at 1, 2, 5, and 10
year follow-ups (see Subjects for actual number of patients who
met for testing) and comprise the 10 year follow-up study group.
MEASURES
Clinical instruments
The structured clinical interview for the DSM-IV; SCID (First
et al., 1995) was used for diagnostic purposes. Trained clinical
research personnel carried out diagnostic evaluations. Symptom
levels were assessed with the Positive and Negative Syndrome
Scale; PANSS (Kay et al., 1987) and global functioning with the
Global Assessment of Functioning Scale—split version (GAF).
DUP was measured as the time from the first onset of psy-
chotic symptoms (defined as the first week with a PANSS score
of 4 or more on one of the Positive scale items 1, 3, 5, 6, or
General scale item 9) to the start of first adequate treatment of
psychosis (defined as start of adequate antipsychotic medication
or admission to hospital for treatment of acute psychosis).
Relapse was defined as the reappearance of positive psychotic
symptoms (as defined above) for at least 7 days.
Premorbid functioning was measured using the Premorbid
Adjustment Scale (PAS) (Cannon-Spoor et al., 1982). A previous
analysis identified two premorbid dimensions: social consisting
of PAS items social isolation and peer relationships and aca-
demic which comprise school performance and school adaptation
(Larsen et al., 2004).
Drug and alcohol abuse for the period of 6 months prior to the
start of treatment was assessed by the Alcohol and Drug Use Scale
(Mueser et al., 2003).
Satisfactory inter-rater reliability was found with overall agree-
ment for DSM-IV diagnostic categories at baseline, Kappa: 0.76.
PANSS: ICC (1, 1): 0.88 for positive symptoms, 0.76 for negative
symptoms, and 0.53 for general symptoms (Friis et al., 2003).
Neurocognitive measures
The subtests Similarities, Block Design and Digit Span from
WAIS-R (Wechsler, 1981) were used to calculate an IQ-estimate
at baseline.
The neurocognitive test battery was found to assess five sep-
arate domains validly, as identified in a factor analytic study of
baseline performance (Friis et al., 2002). Between the 5- and
10 year assessments the test battery was slightly revised, and
the present paper follows four of the five original indices over
the 10-year follow-up interval. Two of these four indices; the
Executive Functioning (EF) and Motor Speed (MS), are identi-
cal to the indices identified in the baseline factor analysis (Friis
et al., 2002). The original Working Memory index (WM) is in the
present study replaced by the Verbal Fluency index (VF), since
the Controlled Oral Word Association Test (COWAT) (Spreen
and Strauss, 1998) is the only subtest from the WM-index that
is also represented at 10 year follow-up. Hence, the WM- index
was re-defined as the Verbal Fluency index.
The EF-, MS-, and VF-indices consist of the same test versions
at all follow-up assessments.
For the Verbal Learning index (VL-index), the revised version
of the California Verbal Learning Test (CVLT) was used at 10 year
follow-up; CVLT-II (Delis et al., 2004). The number of words
and trials were identical to the original version used at the pre-
vious assessments, CVLT (Delis et al., 1987). Fusing raw scores
obtained from these two test versions in the same analyses was jus-
tified since equivalency in total learning and long-delay free recall
raw scores is reported in healthy individuals (Delis et al., 2000).
The psychometric characteristics of the Norwegian translation of
the original English CVLT–II have been retained (Bosnes, 2007),
providing support for good equivalency in the two Norwegian
CVLT versions as well. Since the Danish language is very close
to Norwegian, this is assumed to hold true also for the Danish
versions.
Thus, the only change in the test battery in the present study
was the replacement of the CVLT-revised version between 5-and
10 year assessment.
The domain scores were calculated as the mean z-score of the
tests included based onmeans and standard deviations of the total
sample at baseline (N = 213) (Barder et al., 2013). (See Table 1).
SUBJECTS
Two hundred and thirteen patients between 18 and 65 years of age
were assessed at baseline. Of these, 135 volunteered for re-testing
at 1 year follow-up, and of these, 105 at 2 year follow-up. From
this sample, 62 were tested for the fourth time at the 5 year follow-
up, and are described in Barder et al. (2013). Of the 62 patients
at 5 year follow-up, 43 patients were re-tested at 10 year follow-
up. Thus, the group of 43 patients with valid data from all five
assessments spanning the 10 year follow-up period were included
in the present study. This sample is referred to as the follow-up
sample (n = 43). The group of patients who missed at least one
of the five assessments will be referred to as the remaining sample
(n = 170). The present sample includes all those taking part in the
5 year follow-up study (Barder et al., 2013), except for 19 subjects
lost between the 5 and 10 years follow-up.
Baseline demographic and clinical characteristics for the two
samples are presented in Table 2.
The follow-up sample consisted of equal numbers men and
women, they were in their late twenties, and had an estimated
average IQ of around 100. Symptom ratings (PANSS) were severe
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Table 1 | The four neurocognitive indices with the corresponding subtests and raw scores at each time point for the follow-up sample.
Baseline One year Two year Five year Ten year ANOVA
M SD M SD M SD M SD M SD F (4, 39) P η2
Verbal learning—index (VL) 0.25 (0.7) 0.28 (0.78) 0.31 (0.8) 0.20 (0.7) −0.13 (0.9) 2.2 0.089 0.2
CVLT total immediate recall (learning) 56.2 (10.5) 56.4 (13.6) 57.5 (13.5) 56.6 (10.8) 49.9 (12.7)
CVLT delayed free recall 13.0 (2.4) 13.0 (2.6) 12.7 (3.1) 12.7 (2.6) 11.7 (3.4)
CVLT mean errors at recall 0.35 (0.6) 0.29 (0.5) 0.26 (0.4) 0.42 (0.6) 0.47 (0.8)
Motor speed—index (MS) 0.03 (0.8) 0.10 (0.8) 0.19 (0.7) −0.11 (0.6) −0.01 (0.6) 1.8 0.145 0.2
FTT (mean score for the two hands) 48.3 (6.7) 49.0 (7.0) 50.0 (6.0) 47.1 (5.5) 48.0 (5.4)
Executive functioning—index (EF) 0.13 (0.8) 0.22 (0.8) 0.19 (0.9) 0.31 (0.6) 0.21 (0.9) 1.1 0.372 0.1
WCST categories completed 5.3 (1.3) 5.5 (1.4) 5.5 (1.4) 5.6 (0.9) 5.6 (1.5)
WCST perseverative responses 13.6 (13.0) 11.3 (10.0) 12.0 (12.7) 8.9 (6.5) 9.7 (6.4)
WCST attempts to first category 19.0 (14.8) 19.4 (19.4) 19.4 (20.6) 20.4 (20.7) 23.2 (26.5)
Verbal fluency—index (VF) 0.22 (0.7) 0.18 (0.9) 0.31 (1.1) 0.55 (0.86) 0.41 (1.3) 3.0 0.028 0.2
COWAT (sum of F-, A-, and F-words) 34.2 (8.1) 33.8 (10.3) 35.2 (12.0) 37.8 (9.3) 36.3 (14.6)
CVLT, California Verbal Learning Test (Delis et al., 1987, 2004); FTT, Finger tapping test (Lezak, 1995); WCST, Wisconsin Card Sorting Test, (128 cards computer
version) (Heaton et al., 1993); COWAT, Controlled Oral Word Association task (Spreen and Strauss, 1998).
Table 2 | Demographic variables and symptom scores at baseline.
Variable Follow-up sample (n = 43) Remaining sample (n = 170) χ2/t/z p
Age (M, SD) 27.8 (8.8) 28.3 (10.1) t(211) = 0.3 0.787
Gender (Male) 22 (51%) 101 (59%) χ2
(1, 213) = 0.4 0.421
Education (M, SD) 13.1 (2.9) 11.7 (2.2) t(205) = 3.1 0.003
IQ estimate (M, SD) 102.9 (9.0) 97.9 (10.6) t(208) = 2.9 0.005
DUP1 (weeks) (Median, Range) 7 (0–174) 11 (0–966) z = 1.0 0.338
PAS social, childhood (M, SD) 0.8 (0.9) 1.0 (1.1) t(211) = 1.2 0.241
PAS social, change (M, SD) 1.0 (1.4) 0.8 (1.5) t(211) = 1.0 0.365
PAS academic, childhood (M, SD) 1.5 (1.1) 1.8 (1.3) t(211) = 1.1 0.278
PAS academic, change (M, SD) 0.7 (1.4) 0.7 (1.2) t(211) = 0.0 0.970
PANSS Positive score 20.4 (5.1) 20.2 (5.8) t(210) = 0.2 0.860
PANSS Negative score 13.8 (7.4) 15.6 (6.7) t(210) = 1.5 0.122
PANSS General score 34.1 (9.3) 35.6 (10.1) t(209) = 0.9 0.375
GAF-Function score 30.8 (9.4) 32.4 (10.7) t(209) = 0.9 0.374
GAF-Symptom score 28.7 (7.0) 29.7 (7.1) t(209) = 0.8 0.403
Alcohol abuse (N, %) 2 (4.6%) 24 (14.3%) χ2
(1, 212) = 2.9 0.088
Drug abuse (N, %) 8 (18.6%) 39 (23.1%) χ2
(1, 212) = 0.4 0.528
DIAGNOSE, (DSM-IV)
Schizophrenia 10 (23.3%) 47 (27.6%)
Affective psychosis w/ mood incongruent symptoms 5 (11.6%) 24 (14.1%)
Schizoaffective 5 (11.6%) 21 (12.4%)
Schizophreniform 13 (30.2%) 38 (22.4%) χ2
(6, 213) = 4.3 0.637
Delusional disorder 2 (4.7%) 13 (7.6%)
Brief psychotic episode 5 (11.6%) 9 (5.3%)
Psychotic disorder NOS 3 (7.0%) 18 (10.6%)
1Duration of untreated psychosis.
at baseline but rated as mild from 3 months of treatment to
follow-up (data not shown). Significant, differences between the
two samples were found on two baseline measures: the follow-
up sample had slightly longer education and higher IQ-estimate
than the remaining sample. Hence, education and IQ were used
as correcting covariates in follow-up analyses in order to increase
the representativeness of our sample to the total group of TIPS
patients. The diagnostic distribution did not differ significantly
between groups at any of the follow-ups.
GROUPS DEFINED BY PRESENCE OF RELAPSES
The follow-up sample was divided into two groups based
on the number of relapses experienced by the individu-
als during their first year of treatment; no early relapses
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(N = 31), and one to three early relapses” (including 3 con-
tinuously psychotic patients) (N = 12), hereafter referred to as
the “No early relapse-group” and the “Early Relapse-group,”
respectively.
The groups did not differ significantly on demographic vari-
ables (age, gender, estimated IQ, years of education), nor in
childhood academic or social function, or premorbid change in
function (PAS), but the No early-relapse group was character-
ized by a significantly higher symptom load as measured by the
PANSS positive [21.7 vs. 16.9, t(41) = 3.0, p < 0.004] and PANSS
negative symptom scores [15.4 vs. 9.5, t(41) = 2.46, p = 0.018] at
baseline.
The No early relapse-group also performed significantly bet-
ter on the VF-index at baseline [0.37 vs. −0.16, t(41) = 2.22,
p = 0.032], but no group differences were found for the other
neurocognitive indices.
The Early relapse- group had significantly more patients
with a narrowly defined schizophrenia diagnosis (schizophrenia,
schizophreniform, or schizoaffective) at baseline, compared to the
No early-relapse group [χ2(1, 43) = 5.2, p = 0.023].
In order to identify discrepancies in the distributions of scores
between the total sample and the follow-up sample, a screening
of the neurocognitive indices in the total sample (the remain-
ing sample and the follow-up sample) divided by “relapse or not
first year” was carried out. The screening illustrated a pattern of
group differences between the two “relapse groups” consistent
with the results from the follow-up sample over time. The differ-
ences between the “early relapse-group” and the “no-early relapse
group” were slightly more pronounced in the total sample. Thus,
the group differences found in the follow-up sample are assumed
to be a conservative estimate of differences present in the larger
sample.
The follow-up sample was also divided into “Relapse or no
relapse” based on the first 2 years (17 vs. 26), and the first 5
years (26 vs. 17), in order to analyze if any of these groupings
would be better in distinguishing between the two groups’ 10 year
neurocognitive trajectories.
ATTRITION/MISSING DATA
The four index scores consisted of a total of 8 subtests. In cases
of missing data, the group mean was inserted. This applied for
less than 4% of the follow-up sample at the first four time points,
and for 6% of the sample at the 10 year follow-up. The four index
scores were calculated after missing scores were replaced by valid
group mean score obtained at the given time point.
MEDICATION
At the 10 year follow-up assessment 31 patients were using
antipsychotic medication, and 12 patients were not. There was no
significant difference in continued medication between the early
relapse—and the no early-relapse group at 10 year follow-up [83
vs. 68%, respectively, χ2(1, 43) = 1.0, p = 0.307].
STATISTICAL ANALYSIS
Analyses were conducted using the statistical package SPSS
(PAWS) forWindows (version 18). Group differences for continu-
ous variables were evaluated with analyses of variance and t-tests.
Chi-square tests were used for categorical variables.
A within-group repeated measure multiple analysis of vari-
ance, MANOVA, was performed to investigate the neurocognitive
development over time (five assessments) with the four neurocog-
nitive indices as dependent variables.
Four separate One-Way repeatedmeasures ANOVAs were con-
ducted, one for each of the neurocognitive indices, to analyse
change over time.
Follow-up analyses of co-variance (MANCOVA, ANCOVAs),
were performed in order to control for the effect of IQ and edu-
cation over time (variables that differed between the follow-up
and the remaining sample).
The hypothesis of an association between neurocognitive
development and presence of relapse(s) was examined by a second
set of repeated measure MANOVAs and ANOVAs with follow-up
MANCOVAs and ANCOVAs, with “No relapse group”/“Relapse
group” as the between-subject factor, and indices and time as the
within-subject factors. Three sets of relapse or no relapse groups
were defined based on relapse or not within the first year, the
second year, or the fifth year.
Additional repeated measure ANOVAs were conducted on
each of the three subtests that constituted the VL-index to inves-
tigate whether there was a differential relationship to first year
relapse contained in the index score. Follow-up analyses were
performed to control for covariates.
Bonferroni corrections were used to control for multiple
comparisons.
RESULTS
Results for the eight tests and four indices over the five assess-
ments are shown in Table 1. No statistically significant effect of
assessment time was found on the set of the four neurocogni-
tive indices [λ = 0.89, F(4, 39) = 1.2, p = 0.329, η2 = 0.11], nor
did the indices differ significantly from each other irrespective of
time [λ = 0.93, F(3, 40) = 1.0, p = 0.401, η2 = 0.07]. However, a
significant effect was found for the interaction between neurocog-
nitive indices and time [λ = 0.47, F(12, 31) = 2.9, p = 0.007,
η2 = 0.53].
When analysing change in performance over time for each
index, we found a significant effect of time for Verbal Fluency
only; performance increased linearly from baseline to the 10
year follow-up. A near significant curvilinear (quadratic) devel-
opment was found for Verbal Learning, where performance
remained unchanged from baseline until the 2 year assessment
and decreased progressively at the 5 and 10 year assessments.
The mean scores over time for the four neurocognitive dimen-
sions are displayed in Figure 1.
After controlling for IQ and education, the effect of assessment
time and indices remained non-significant, but the interaction
effect between time and indices lost its significance [λ = 0.58,
F(12, 28) = 1.7, p = 0.123, η2 = 0.42]. Since the effect size is still
classified as large, the non-significant finding can be attributed to
low statistical power due to small number of subjects within each
group.
When analysing the effect of relapses during the first year on
neurocognitive performance over the 10 year follow-up, a signifi-
cant three-way interaction was found (Time × Indices × Relapse
group), in addition to all two-way interactions and main effect of
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FIGURE 1 | Neurocognitive indices from baseline to 10 year follow-up.
Table 3 | Results from MANOVA; effects of early relapse on
neurocognitive indices over time.
MANOVA F df p η2
Time 0.2 4.38 0.925 0.02
Indices 0.5 3.39 0.686 0.04
Relapse(s) first year1 4.6 1.41 0.038* 0.10
Time × Indices 2.8 12.30 0.010** 0.53
Time × Relapse(s) first year 4.3 4.38 0.006** 0.31
Indices × Relapse(s) first year 5.7 3.39 0.002** 0.31
Time × Indices × Relapse(s) first year 2.8 12.30 0.010** 0.53
1Total relapses first year: “No relapse first year” (N = 31), “Relapse(s) first year”
(N = 12). *p < 0.05; **p ≤ 0.01.
relapse-group (see Table 3). When controlling for IQ and educa-
tion, the three-way interaction remained significant [F(12, 27) =
2.2, p = 0.046, η2 = 0.49].
Analyses addressing the association between neurocognitive
course and relapses within the first 2-, and 5-years, respectively,
gave the following results; the 2-year grouping gave a signifi-
cant interaction between indices and time [F(12, 30) = 2.9, p =
0.009, η2 = 0.50], and indices and relapse groups [F(3, 39) = 4.1,
p = 0.012, η2 = 0.20]. The 5-year grouping gave a significant
interaction between indices and time [F(12, 30) = 2.8, p = 0.012,
η2 = 0.50], and a main effect of group [F(1, 41) = 10.5, p =
0.002, η2 = 0.20]. However, no significant interactions were
found between time and relapse-groups, or any three-way inter-
actions, as was the case for grouping with relapses first year as
shown in Table 3.
Follow-up analyses with separate repeated measures ANOVA
with “relapse(s) first year” as the between-subjects variable
revealed significant interactions between relapse and all neu-
rocognitive indices except Executive Function. For Verbal Fluency
the no early-relapse group performed better than the early
relapse-group at all time points, and for Verbal Learning signif-
icantly so at the 1 and 2 year follow-ups (see Figures 2–4).
After controlling for IQ and education the result remained
significant for Verbal Learning and Verbal Fluency.
Because the VL-index consists of three subtests from the CVLT
(see Table 1), further analyses were conducted to investigate if any
FIGURE 2 | Verbal Learning index from baseline to 10 year follow-up,
split by early relapse.
FIGURE 3 | Verbal Fluency index from baseline to 10 year follow-up,
split by early relapse.
of these were more strongly related to relapses first year. A signifi-
cant change over time was identified for the total learning score
over five trials [F(4, 38) = 5.8, p = 0.001, η2 = 0.40]. The total
learning score decreased from baseline to 10 years, with a signif-
icant main effect of relapse-group and a time by relapse-group
interaction, indicating that the group with one or more relapses
within the first year had a more prominent decline over the 10
year follow-up interval. A significant interaction between time
and relapse-group was also found for the delayed free recall sub-
test [F(4, 38) = 4.6, p = 0.002, η2 = 0.35], but no main effect of
group. No significant effects were found for mean recall errors.
The results remained significant after controlling for IQ and
education.
DISCUSSION
There are few studies investigating the relationship between
neurocognitive and clinical variables over time, and stud-
ies addressing specific neurocognitive areas that may help
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FIGURE 4 | Motor Speed index from baseline to 10 year follow-up, split
by early relapse.
differentiate this relationship are virtually absent. We aimed
to investigate these issues in a well described sample of forty-
three FEP patients followed over five assessments spanning
10 years.
Our first finding demonstrates overall neurocognitive stabil-
ity over the 10 year follow-up period. The current study is one
of the longest follow-up studies to date of FEP patients, and is
supporting evidence of gradual cognitive stabilization in FEP over
time (Bozikas and Andreou, 2011). However, as gradual stabiliza-
tion is a group effect and may obscure substantial heterogeneity
across individuals, we hypothesized that separating the sample
based on presence of one or more relapses or non-remission
of psychosis could differentiate the neurocognitive course. This
hypothesis was supported for relapses within the first year, as
the two groups showed different trajectories in three of the four
neurocognitive indices over the 10 year follow-up period (see
Figures 2–4). After controlling for IQ and education the group
difference remained significant for Verbal Learning and Verbal
Fluency, indicative of a specific neurocognitive change related to
illness severity.
Analyses of relapse or not within the first 2- or 5-year follow-
ups did not demonstrate the same differentiating effect for the
neurocognitive trajectories. Psychotic relapse early on in the
illness serves as the most potent prediction of neurocognitive
deterioration over time.
The findings are in accordance with our previous report from
the 5-year follow-up of the current patient sample (Barder et al.,
2013) where numbers of relapses within the first 5 years after
start of treatment were significantly related to a decrease in the
VL-index over time. Conversely, subjects with no re-occurring
episodes did not experience this decline. Based on the findings
in the current study, a long term interaction between symptoma-
tology and neurocognition appears to be present already 1 year
after treatment initiation.
One of the few longitudinal studies of FEP reported a relation-
ship between neurocognition and psychotic symptoms in the first
4–5 years (Hoff et al., 1999), but no associations using difference
scores from baseline to 10 years follow-up (Hoff et al., 2005).
The authors suggested that improvement in symptomatologymay
have a greater effect on cognitive abilities earlier in the illness but
that its effects are diminished over time (Hoff et al., 2005).
Findings in the present study may be said to contradict such an
hypothesis, as early remission of positive symptoms (no relapse)
is associated with better neurocognitive performance at all follow-
up assessments, and at 10 years follow-up for certain areas of
neurocognitive functioning. On the other hand, if the concept of a
critical period (Birchwood et al., 1998) is applied in this context, a
long-term relationship between early relapse and neurocognitive
course may be manifested through a sensitive first year period.
Thus, early reduction in symptomatology (illness severity) may
have a greater direct effect on neurocognition early in the illness,
which is thenmediating the subsequent long-term neurocognitive
course.
Based on these premises, it is tempting to conclude that early
re-occurrence of psychotic episodes may affect the neurocogni-
tive course both earlier in the illness [as found in Barder et al.
(2013)] and over as long as 10 years after start of treatment, at
least for some neurocognitive areas. Moreover, neurocognitive
dysfunction has recently been found to be more related to his-
tory of psychosis than to diagnostic category among bipolar and
schizophrenia patients (Simonsen et al., 2011), also supporting
a relationship between psychosis and neurocognitive functioning
over time.
Some detailed explanation of the mechanisms behind this
hypothetical process would presumably involve advanced mea-
sures of both brain structures and networks, which lies beyond
the area of neurocognition and the scope of this study. However,
one might speculate that recurring episodes early in the course of
illness may serve as a vulnerability factor, leading toward a poten-
tially vicious circle of truncation of education and employment,
psychosocial challenges, more medication and medication non-
adherence, which together may increase the risk of new psychotic
episodes.
The method applied in this paper implies associations and
does not allow a conclusion based on causality. Cognitive impair-
ment could be the cause rather than the consequence of poorer
clinical course. Nonetheless, detecting a relationship between
relapse in the early phase and the long-term neurocognitive devel-
opment may have significant clinical value for specific subgroups
of patients. Hence, the findings may be taken as support for the
relevance of early detection teams, as identifying subgroups with
a possible vulnerability to neurocognitive impairments would be
essential for rehabilitation and treatment programs.
In the present study, the relationship between early relapse
and the continuing neurocognitive course was nuanced by the
finding of a differentially stronger association for one subtest in
the VL-index. Analysing the three subtests separately identified
the encoding stage as the strongest factor related to early relapse.
This indicates a differential relationship between psychosis and
specific areas of neurocognition. Similar hypotheses have been
proposed previously, through the concept of cognitive endophe-
notypes (Bilder et al., 2000; Barrett et al., 2009). In the present
study, verbal learning is indicated as a relatively more vulnerable
neurocognitive function in terms of associations with early recur-
rent psychotic episodes. These results are also in agreement with
studies reporting that a lower performance on verbal memory was
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found to identify individuals with FEP with a poor outcome after
6 months of treatment (Bodnar et al., 2008).
There is, however, some controversy surrounding findings in
this realm. For example, a meta-analysis assessing 70 studies of
patients with schizophrenia found that clinical variables such
as duration of illness, severity of psychopathology, and positive
symptoms did not appear to influence the magnitude of memory
impairment. Thus, the memory impairment was found to be of
a considerable robustness and not readily moderated by variables
that may seem relevant (Aleman et al., 1999).
Although these are compelling data, the robust nature ofmem-
ory impairments in psychotic disorders is not fully identified
until the long-term perspective is better understood. This is a
very comprehensive task, and not likely to be answered on the
basis of cross-sectional studies alone. In addition, the relationship
between memory and clinical variables is inevitably complex due
to the large heterogeneity in the FEP population e.g., (Lindsberg
et al., 2009). Hence, it is of considerable interest to identify sub-
groups with weaker neurocognitive performance in order to adapt
treatment and rehabilitation efforts accordingly. A possible sensi-
tive period around first year after treatment initiation may give
valuable information on this matter.
In the present paper we investigated if the presence of early
relapses could differentiate longitudinal cognitive trajectories. In
answering this question, one of the most relevant neurocogni-
tive domains may be the verbal memory domain in general and
the encoding stage in particular. This is consistent with a thor-
ough review of verbal memory dysfunctions in schizophrenia,
also reporting that the “memory” deficit appears primarily to be a
learning impairment, and not merely the result of a problem with
retrieval. Thus, it appears clear that the primary deficit is during
the encoding stage of memory formation (Cirillo and Seidman,
2003).
Whether the decline in the present study has a clinical rel-
evance is another question. The change in raw scores may not
be clinically significant for the average follow-up sample, but
the change between the relapse-groups may translate to a clin-
ical level. Further, these findings are important in that they
contrast a general notion of a clear improvement or a stable long-
term course of neurocognition in FEP. A comparison between
the relapse- and the no-relapse group at 2 year follow-up (the
point of maximum discrepancy between groups), showed a dif-
ference of 16 words in favor of the no-relapse group. Although
this discrepancy decreases again over time (Figure 2), we find
it interesting for several reasons; the foundation for treatment
adherence is often set in the first years after start of treatment
(Masand et al., 2009). We would assume that for clinical ther-
apy, and perhaps also for antipsychotic medication, the ability to
adhere to, and benefit from treatment may be reduced in patients
experiencing difficulties with encoding and memory of verbal
auditory information. The issue of clinical significance is multi-
faceted, and thus, experienced clinical implications should not be
ruled out.
Memory impairments are by no means exclusive to psy-
chotic disorders, but are found in a range of other psychi-
atric illnesses, e.g., in major depressive disorder (Bora et al.,
2009). Some studies have compared memory performance in
clinical groups with major depression and schizophrenia, indi-
cating impaired memory and especially impaired acquisition,
as a particularly sensitive indication of schizophrenia, also after
controlling for IQ and clinical symptom load (Egeland et al.,
2003). Findings in the present study are in accordance with
this, as the “Early-relapse”-group consisted of significantly more
patients with a narrowly defined schizophrenia diagnosis at base-
line. Such findings help emphasize, albeit indirectly, that verbal
learning and memory may be key areas for further investi-
gations of the long term neurocognitive course in psychotic
illnesses.
In a longitudinal design several limitations need to be dis-
cussed, and possible re-test effects are a relevant concern in
this regard. However, the relatively different trajectories found
between the two groups reduce the likelihood of a strong re-test
effect.
The degree of neurocognitive change is generally based upon
comparison to patients’ baseline performance. In the present
study the patients were assessed after remission of the psychotic
symptoms, or after 3 months, resulting in a relatively low level of
symptoms at the time of the first test. This definition of baseline
is likely to result in better neurocognitive performance compared
to a baseline defined several weeks earlier. Thus, the broad defini-
tion of baseline applied in this study may have contributed to our
findings of stability at group level, instead of a small increase as is
reported in some studies (Gold et al., 1999).
A key aspect in the present study is to challenge the notion
of a “group level” and explore subgroups that may show differ-
ent neurocognitive trajectories. The question of whether there are
subgroups with divergent paths embedded in a larger sample is
not necessarily dependent upon a healthy control group for com-
parison; the patients’ first assessment constitutes the reference
point, which is followed-up along with assessments of the clinical
development.
However, another point should be noted regarding the repre-
sentativeness of the early relapse group. This group is small (n =
12), and had significantly lower PANSS positive and PANSS nega-
tive symptom scores at baseline (See Groups Defined by Presence
of Relapse), indicating better functioning in terms of symptom
load. Although this implies caution regarding direct generaliza-
tion to a larger population, our results may in fact underestimate
the magnitude of true differences between relapse and no-relapse
samples over time.
The No early-relapse group had a significantly shorter DUP
than the early relapse-group. This indicates a potentially large
variation in the definition of “early phase” clinical characteris-
tics used throughout the paper. However, a previous report from
the TIPS-study found no significant association between DUP
and neurocognitive functioning in the larger sample (Rund et al.,
2004).
The follow-up sample in the present study had a significantly
higher IQ and one more year of education than the remaining
sample at baseline. Although results remained significant despite
controlling for these variables in analyses, the follow-up sample is
a relatively high-functioning sample in terms of cognition. Thus,
conclusions regarding the larger population are not directly trans-
ferable, and must be drawn with caution. Yet, this implies that a
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more representative sample of early/no-early relapse patients may
possibly demonstrate a more distinct neurocognitive discrepancy
over time.
Due to lack of a control group we utilized comparisons to nor-
mative data to evaluate the (possible) effects of aging. For the
VL-index (CVLT and CVLT-II tests), the expected change in stan-
dard norms is small or non-existent for both genders, suggesting
that no (or very limited) age-related decline is expected.
CONCLUSION
The results of our study have demonstrated overall 10 year neu-
rocognitive stability after the start of treatment of FEP. Further,
our findings identify possible neurocognitive subgroups based on
early recurrent psychotic episodes, and support previous research
identifying verbal memory as a neurocognitive function that is
relatively more vulnerable to the effects of psychosis. Even if
the design in this study does not allow drawing causal infer-
ences, we have dissociated the encoding stage (acquisition of a
list of words) as the only subtest from the VL-index showing a
significant decrease over time. The relationship between verbal
memory deficits and psychosis has been widely documented in
the early stages of psychotic illness, but the longitudinal develop-
ment of verbal memory in relation to clinical characteristics, is
not yet clear. It is relevant to note that amongst papers examining
FEP and neurocognition longitudinally, a large subset conclude
on trends of stability, without investigating subgroups that may
show significant change over time. Thus, both early illness sever-
ity, as measured by the presence of relapses, and the arena of
verbal learning and memory, may be important factors in this
regard.
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